Haley Melikian

Has grant

Professor

University of Massachusetts Chan Medical School
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Haley Melikian is a Professor at the University of Massachusetts Medical School in the United States. Her research focuses on dopamine transporter trafficking and the mechanisms of action involving Rit2 GTPase, as highlighted in her recent articles. Her work contributes to the understanding of neurobiology and transport mechanisms in vivo.

Recent Grants

Grant: Close

Dopamine Transporter: Tools for in vivo molecular replacement

Open Date: 2020-04-01

Close Date: 2022-03-01

Grant: Close

Trafficking and Regulation of Monoamine Transporters

Open Date: 2002-05-01

Close Date: 2018-08-31

Articles (4)

The dopamine (DA) transporter (DAT) is a major determinant of DAergic neurotransmission, and is a primary target for addictive and therapeutic psychostimulants. Evidence accumulated over decades in cell lines and in vitro preparations revealed that DAT function is acutely regulated by membrane trafficking. Many of these findings have recently been validated in vivo and in situ, and several behavioral and physiological findings raise the possibility that regulated DAT trafficking may impact DA signaling and DA‐dependent behaviors. Here we review key DAT trafficking findings across multiple systems, and discuss the cellular mechanisms that mediate DAT trafficking, as well as the endogenous receptors and signaling pathways that drive regulated DAT trafficking. We additionally discuss recent findings that DAT trafficking dysfunction correlates to perturbations in DA signaling and DA‐dependent behaviors. image

Year:

2024

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease and arises from dopamine (DA) neuron death selectively in the substantia nigra pars compacta (SNc). Rit2 is a reported PD risk allele, and recent single cell transcriptomic studies identified a major RIT2 cluster in PD DA neurons, potentially linking Rit2 expression loss to a PD patient cohort. However, it is still unknown whether Rit2 loss itself impacts DA neuron function and/or viability. Here we report that conditional Rit2 silencing in mouse DA neurons drove motor dysfunction that occurred earlier in males than females and was rescued at early stages by either inhibiting the DA transporter (DAT) or with L-DOPA treatment. Motor dysfunction was accompanied by decreased DA release, striatal DA content, phenotypic DAergic markers, DA neurons, and DAergic terminals, with increased pSer129-alpha synuclein and pSer935-LRRK2 expression. These results provide clear evidence that Rit2 loss is causal for SNc cell death and motor dysfunction, and reveal key sex-specific differences in the response to Rit2 loss.

Year:

2024

Year:

2020

Year:

2020

Collaborators (1)

Zhenyu Yue

Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details